Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Silmitasertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib
    Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib

    20 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-ii--study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-associated-with-viral-infection-in-taiwan-302094217.html

    PR NEWSWIRE
    20 Mar 2024
    Share Share
    Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib
    Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib

    21 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-received-us-fda-ind-approval-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301994554.html

    PR NEWSWIRE
    21 Nov 2023
    Share Share
    Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib
    Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib

    09 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-successfully-dosed-in-taiwan-phase-ii-study-of-silmitasertib-in-hospitalized-adults-with-covid-19-301982962.html

    PR NEWSWIRE
    09 Nov 2023
    Share Share
    Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib
    Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib

    19 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301961780.html

    PR NEWSWIRE
    19 Oct 2023
    Share Share
    Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib
    Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib

    02 May 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=157818&sid=2

    PHARMABIZ
    02 May 2023
    Share Share
    Senhwa Presents Positive Initial Data from Trial of Silmitasertib at AAD
    Senhwa Presents Positive Initial Data from Trial of Silmitasertib at AAD

    28 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/at-the-2022-aad-annual-meeting-senhwa-presents-positive-initial-data-from-clinical-trial-of-silmitasertib-used-to-treat-patients-with-advanced-basal-cell-carcinoma-301511415.html

    PRNEWSWIRE
    28 Mar 2022
    Share Share